Skip to Content


In the US, Urokinase (urokinase systemic) is a member of the drug class thrombolytics and is used to treat Deep Vein Thrombosis, Heart Attack, Pulmonary Embolism and Thrombotic/Thromboembolic Disorder.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Anticoagulant agent: Fibrinolytic enzyme

Chemical Names

A plasminogen activator isolated from human sources (WHO)

Human urokinase (IUPAC)

Foreign Names

  • Urokinasum (Latin)
  • Urokinase (German)
  • Urokinase (French)
  • Uroquinasa (Spanish)

Generic Names

  • Urochinasi (OS: DCIT)
  • Urokinase (OS: BAN, USAN, JAN, DCF)
  • Urokinase (PH: BP 2015, JP XVI, Ph. Eur. 8)
  • Urokinasum (PH: Ph. Eur. 8)

Brand Names

International Drug Name Search


BANBritish Approved Name
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
IUPACInternational Union of Pure and Applied Chemistry
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.